Neon Therapeutics
Neon Therapeutics was a clinical-stage biotech (founded 2015, Cambridge, MA) that developed personalized neoantigen cancer vaccines based on technology from Dana-Farber and the Broad Institute. Acquired by BioNTech in 2020, its platform was integrated into the iNeST pipeline.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Neon Therapeutics firmographics
Firmographics- Name
- Neon Therapeutics
- Website
- https://neontherapeutics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Neon Therapeutics was a clinical-stage biotech (founded 2015, Cambridge, MA) that developed personalized neoantigen cancer vaccines based on technology from Dana-Farber and the Broad Institute. Acquired by BioNTech in 2020, its platform was integrated into the iNeST pipeline.
- Ownership category
- akta.pro rank
Neon Therapeutics industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
- akta.pro secondary industries
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where Neon Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Neon Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Neon Therapeutics product offering
Product offeringCore offering
Neon Therapeutics developed a personalized neoantigen cancer vaccine platform that custom-designs therapeutic cancer vaccines based on individual tumor mutations using mRNA technology. The platform was originally developed at Dana-Farber Cancer Institute and the Broad Institute, and was acquired by BioNTech in 2020, with the technology integrated into BioNTech's iNeST pipeline. The platform is undergoing clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- Personalized Neoantigen Cancer Vaccine Platform
Companies that use Neon Therapeutics
Customer profileIdeal customer profiles2 records
Neon Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Neon Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BioNTechcoreBioNTech acquired Neon Therapeutics in 2020 to advance the personalized neoantigen cancer vaccine platform. The technology, originally developed at Dana-Farber Cancer Institute and the Broad Institute, has been integrated into BioNTech's iNeST pipeline and is undergoing multiple clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer. This acquisition represents a core strategic integration for BioNTech's cancer immunotherapy portfolio.
Neon Therapeutics competitors and assessment
Company assessmentDirect peers
- CureVac: CureVac develops mRNA-based cancer vaccines and therapeutics, including personalized neoantigen programs. It is a direct peer in mRNA cancer vaccine technology, though with broader infectious disease exposure.
- Moderna: Moderna develops mRNA-4157, a leading personalized neoantigen cancer vaccine in late-stage melanoma trials with Merck. Comparable to Neon in using mRNA technology to encode patient-specific tumor neoantigens, and a direct competitor in the same product category.
- Gritstone bio: Gritstone bio develops personalized neoantigen immunotherapies (SLATE and GRANITE programs) using a similar tumor-mutation-targeting approach. It is a direct competitor to Neon's platform in personalized cancer vaccine development.
- BioNTech: BioNTech is Neon's parent company following the 2020 acquisition and the operator of the iNeST pipeline that integrates Neon's personalized neoantigen vaccine platform. BioNTech's internal FixVac and iNeST programs make it both the acquirer and the closest direct comparator in personalized cancer vaccines.
Emerging players
- Agenus: Agenus develops immuno-oncology therapies including neoantigen vaccines and checkpoint antibodies. An emerging player with overlapping vaccine and combination strategy relevant to Neon's positioning.
- Transgene: Transgene develops individualized immunotherapy including TG4050, a personalized neoantigen vaccine using viral vector technology. Comparable emerging player in patient-specific cancer vaccines with a different delivery modality but similar targeting logic.
- Genocea Biosciences: Genocea developed personalized neoantigen cancer vaccines (GEN-009) using a similar tumor-mutation-targeting approach. Comparable emerging player in personalized cancer immunotherapy, though smaller and earlier stage.
Broad incumbents
- Genentech (Roche): Roche/Genentech is a broad immuno-oncology incumbent with Tecentriq and a pipeline of personalized cancer vaccine programs through partnerships. Comparable as a large incumbent pursuing neoantigen-based combinations.
- Merck: Merck's Keytruda (pembrolizumab) is the dominant checkpoint inhibitor used in combination with personalized neoantigen vaccines like Neon's. Broad incumbent in immuno-oncology and a strategic partner/competitor in the combination therapy market.
Others
- Personalis: Personalis provides genomic profiling and neoantigen identification services used to support personalized cancer vaccine design. It is an enabling technology peer that supports similar vaccine developers rather than a direct competitor.
Market position
Customer concentration
Neon Therapeutics social profiles
Digital presenceNeon Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neon Therapeutics leadership team
Management profileNumber of profiles
Neon Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neon Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neon Therapeutics
What does Neon Therapeutics do?
Neon Therapeutics developed a personalized neoantigen cancer vaccine platform that custom-designs therapeutic cancer vaccines based on individual tumor mutations using mRNA technology. The platform was originally developed at Dana-Farber Cancer Institute and the Broad Institute, and was acquired by BioNTech in 2020, with the technology integrated into BioNTech's iNeST pipeline. The platform is undergoing clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer.
Is Neon Therapeutics a public or private company?
Neon Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Neon Therapeutics founded?
Neon Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Neon Therapeutics based?
Neon Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Neon Therapeutics's main competitors?
Direct peers on record are CureVac, Moderna, Gritstone bio and BioNTech. Emerging players are Agenus, Transgene and Genocea Biosciences. Broad incumbents are Genentech (Roche) and Merck. Personalis is listed as an others.
Does Neon Therapeutics have an API?
No public API is recorded for Neon Therapeutics.
What industry is Neon Therapeutics in?
Neon Therapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.